摘要
目的:探讨布洛芬口服治疗新生儿呼吸窘迫综合症(NRDS)患儿发生动脉导管未闭(PDA)的有效性和安全性。方法:32例NRDS发生PDA的早产儿随机分成两组,一组口服布洛芬混悬液,另一组口服吲哚美辛,记录每天尿量、黄疸、消化道出血等情况,48 h后再次予心脏彩色超声多谱勒检查。结果:总有效率两组比较无显著性差异;不良反应布洛芬组明显优于消炎痛组,有显著性差异。结论:布洛芬混悬液治疗早产儿PDA具有疗效好,不良反应少,临床应用限制较少的优点。
Objective： To discuss the safety and efficacy of oral ibuprofen in h＇eatment of patent ductus arteriosus （PDA） with neonatal respiratory distress syndrome （NRDS）, Methods： 32 premature infants in PDA with NRDS divide into two groups. One group was given oral ibuprofen suspension and the other oral indomethacin. The urine output and jaundice and gastrointestinal hemorrhage etc were recorded every day during the clinical course . Results： The two groups＇ efficacy had no marked difference; the side-effects of ibuprofen group was obviously less than those of indomethacin group. Conclusion： Oral ibuprofen in treatment of patent ductus arteriosus with neonatal respiratory distress syndrome has better efficacy and fewer side effects and fewer limits than indomethacin,
出处
《儿科药学杂志》
CAS
2005年第5期25-26,共2页
Journal of Pediatric Pharmacy
关键词
布洛芬
吲哚美辛
新生儿
呼吸窘迫综合症
动脉导管未闭
早产儿
Ibuprofen
Indomethacin
Neonatal
Respiratory distress syndrome
Patent ductus arteriosus
Premature infants
